Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
247actual
Sites
47
Countries
Denmark, Italy, Japan +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-25 | actual | When the study began enrolling |
| Primary completion | 2025-05-06 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-05-06 | estimated | The whole study's end, after follow-up |
| First posted | 2019-05-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-01-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Osimertinib — also filed as TAGRISSO
- Drug: Savolitinib
- Drug: Gefitinib — also filed as Iressa
- Drug: Necitumumab — also filed as Portrazza
- Drug: Durvalumab — also filed as IMFINZI
- Drug: Carboplatin
- Drug: Pemetrexed
- Drug: Alectinib — also filed as Alecensa
- Drug: Selpercatinib — also filed as Loxo-292, Retevmo, Retsevmo
- Drug: Selumetinib — also filed as Koselugo
- Drug: Etoposide
- Drug: Cisplatin
- Drug: Datopotamab deruxtecan — also filed as DS 1062a
Primary outcome
what the primary-completion date above is the date OFObjective response rate (ORR)
measured Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average
Publications
- PMID 42361644 — linked by the registry
- PMID 41780641 — linked by the registry
- PMID 41130408 — linked by the registry
- PMID 40466026 — linked by the registry
- PMID 39521433 — linked by the registry
- PMID 34389237 — linked by the registry
- PMID 32027845 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed